Vaxart (VXRT) Competitors $0.62 +0.02 (+2.70%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VXRT vs. HUMA, PRTC, MREO, ANAB, CRMD, XERS, ABVX, RNAC, MGTX, and GLUEShould you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Humacyte (HUMA), PureTech Health (PRTC), Mereo BioPharma Group (MREO), AnaptysBio (ANAB), CorMedix (CRMD), Xeris Biopharma (XERS), ABIVAX Société Anonyme (ABVX), Cartesian Therapeutics (RNAC), MeiraGTx (MGTX), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Vaxart vs. Humacyte PureTech Health Mereo BioPharma Group AnaptysBio CorMedix Xeris Biopharma ABIVAX Société Anonyme Cartesian Therapeutics MeiraGTx Monte Rosa Therapeutics Humacyte (NASDAQ:HUMA) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment. Does the media prefer HUMA or VXRT? In the previous week, Humacyte had 42 more articles in the media than Vaxart. MarketBeat recorded 43 mentions for Humacyte and 1 mentions for Vaxart. Humacyte's average media sentiment score of 0.17 beat Vaxart's score of 0.00 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 10 Very Positive mention(s) 5 Positive mention(s) 23 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Vaxart 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is HUMA or VXRT more profitable? Humacyte has a net margin of 0.00% compared to Vaxart's net margin of -431.61%. Vaxart's return on equity of -110.46% beat Humacyte's return on equity.Company Net Margins Return on Equity Return on Assets HumacyteN/A -942.81% -93.82% Vaxart -431.61%-110.46%-62.78% Do analysts prefer HUMA or VXRT? Humacyte currently has a consensus target price of $13.43, suggesting a potential upside of 189.41%. Vaxart has a consensus target price of $3.00, suggesting a potential upside of 384.18%. Given Vaxart's higher possible upside, analysts clearly believe Vaxart is more favorable than Humacyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Vaxart 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, HUMA or VXRT? Vaxart has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$1.57M371.97-$110.78M-$1.34-3.46Vaxart$20.14M7.00-$82.46M-$0.41-1.51 Do insiders & institutionals have more ownership in HUMA or VXRT? 44.7% of Humacyte shares are owned by institutional investors. Comparatively, 18.0% of Vaxart shares are owned by institutional investors. 11.2% of Humacyte shares are owned by company insiders. Comparatively, 2.6% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community believe in HUMA or VXRT? Vaxart received 278 more outperform votes than Humacyte when rated by MarketBeat users. Likewise, 65.54% of users gave Vaxart an outperform vote while only 65.31% of users gave Humacyte an outperform vote. CompanyUnderperformOutperformHumacyteOutperform Votes3265.31% Underperform Votes1734.69% VaxartOutperform Votes31065.54% Underperform Votes16334.46% Which has more volatility and risk, HUMA or VXRT? Humacyte has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. SummaryHumacyte and Vaxart tied by winning 9 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VXRT vs. The Competition Export to ExcelMetricVaxartBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$137.24M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-1.5146.7390.0517.18Price / Sales7.00415.011,117.14116.99Price / CashN/A182.1043.0437.86Price / Book1.633.894.784.78Net Income-$82.46M-$42.21M$120.31M$225.60M7 Day Performance4.66%-2.15%-1.92%-1.23%1 Month Performance3.39%4.20%11.51%3.36%1 Year Performance3.27%18.39%30.61%16.60% Vaxart Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VXRTVaxart1.5303 of 5 stars$0.62+2.7%$3.00+384.2%+2.8%$137.24M$20.14M-1.51109HUMAHumacyte3.3447 of 5 stars$4.24+3.4%$13.00+206.6%+69.3%$533.64M$1.57M-3.06150Analyst ForecastGap UpPRTCPureTech Health1.9898 of 5 stars$22.20+9.1%$45.00+102.7%+3.8%$531.51M$3.33M0.00100Gap DownHigh Trading VolumeMREOMereo BioPharma Group2.0953 of 5 stars$3.33-11.0%$7.40+122.2%+68.3%$516.64M$1M0.0040ANABAnaptysBio2.3025 of 5 stars$16.92+8.5%$45.09+166.5%-25.4%$514.88M$17.16M-2.80100Analyst ForecastCRMDCorMedix1.8419 of 5 stars$8.44+0.7%$15.20+80.1%+147.0%$512.11M$12.26M-10.3530Analyst ForecastNews CoveragePositive NewsXERSXeris Biopharma3.6008 of 5 stars$3.40+3.7%$4.87+43.1%+73.6%$506.87M$163.91M-7.29290News CoveragePositive NewsABVXABIVAX Société Anonyme2.1824 of 5 stars$8.00+12.5%$38.67+383.3%-27.6%$506.78MN/A0.0061Positive NewsGap DownRNACCartesian Therapeutics2.2994 of 5 stars$19.70+5.4%$43.00+118.3%-6.3%$500.77M$26M-0.3537Analyst ForecastNews CoverageMGTXMeiraGTx3.8637 of 5 stars$6.40+4.6%$23.50+267.2%+25.3%$500.18M$13.93M-5.06300News CoverageGLUEMonte Rosa Therapeutics1.9132 of 5 stars$7.82+3.4%$16.00+104.6%+28.3%$480.44M$14.98M-4.1390Analyst DowngradeNews Coverage Related Companies and Tools Related Companies Humacyte Competitors PureTech Health Competitors Mereo BioPharma Group Competitors AnaptysBio Competitors CorMedix Competitors Xeris Biopharma Competitors ABIVAX Société Anonyme Competitors Cartesian Therapeutics Competitors MeiraGTx Competitors Monte Rosa Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VXRT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VXRT Stock Alerts